SOLFEN-TECH® PLATFORM
Closing the analgesic gap in global livestock production
Medical Ethics is a platform biopharma company built on a single clinical insight: from the moment of injury, there is a window of uncontrolled pain that no Non-Steroidal Anti-inflammatory Drug (NSAID) can reach. The Solfen-Tech Platform (Tri-Solfen®) was designed to close it. We are commercialising that solution as the new standard of care across global livestock production.
PLATFORM AT A GLANCE
Animals treated since commercial launch (2006)
Patents granted globally including EU and USA
Countries with regulatory approval or registration
Regulatory clinical trials
Independent peer-reviewed studies published
Registered treatment for FMD
Only approved topical combination anesthetic & antiseptic for painful procedures and disease-associated lesions in livestock globally.
Moving beyond ad-hoc treatment to mandated welfare outcomes
Global regulation, retailer standards, and veterinary protocols are shifting rapidly. What was once optional for livestock producers is now becoming a mandatory requirement for market access.
Welfare Regulation
New global mandates are making pain relief a legal requirement.
Supply Chain Standards
Major retailers now require proof of welfare to protect their social license.
Veterinary Protocol
Leading vets are embedding pain mitigation into standard clinical care.
One Health & AMR
Smarter antiseptic use to reduce global antibiotic dependence.
THE MEDICAL ETHICS VALUE PROPOSITION
Where Animal Welfare Meets Compounding Commercial Growth
We sit at the intersection of welfare, integrity, and performance — a unique strategic position that converts clinical science into mandated global protocols.
Closing the analgesic gap, from moment of injury
The clinical case for Solfen-Tech begins with the analgesic gap: the window of unchecked nociception between injury and NSAID onset. Regulatory-grade evidence across 25 clinical studies and 44 peer-reviewed publications confirms that Solfen-Tech closes this gap with 30-second onset, sustained wound-site anaesthesia through the wound depot mechanism, and a safety profile validated across cattle, sheep, pigs, and horses. This evidence converts welfare science into licensable market rights.
Complementary phase coverage, not competition with NSAIDs
Solfen-Tech and NSAIDs operate on distinct mechanisms and non-overlapping phases. Tri-Solfen provides acute nociceptive block via sodium channel inhibition. NSAIDs address the systemic inflammatory phase via COX inhibition. Combined, they provide full-spectrum pain control. The cetrimide component adds bactericidal protection, preventing secondary infection from driving a further pain escalation cycle, and directly supporting global AMR stewardship frameworks.
Welfare as a measurable ROI
Performance closes the loop. Faster wound healing, improved weight gain, and reduced post-procedural mortality are documented outcomes. Once protocols embedding the Solfen-Tech platform brands (Tri-Solfen / Multi-Solfen / Equi-Solfen) are adopted, retention and scale are structurally enforced through retailer and assurance scheme compliance requirements, creating recurring, non-discretionary demand.
THE UNMET NEED
A Billion Animals. A Preventable Gap.
Globally, over one billion animals undergo invasive procedures annually. From the moment of incision, there is a window of uncontrolled nociception that systemic NSAIDs cannot reach: the analgesic gap. It begins at injury. It ends only when the NSAID reaches its therapeutic threshold, often hours later. In between, pain is unchecked.
Solfen-Tech closes this gap at the wound site, with onset from 30 seconds, sustained local anaesthesia through the wound depot mechanism, and bactericidal antiseptic protection that prevents the secondary infection cascade that drives pain escalation.
Regulation is accelerating this transition from optional to obligatory. We are not advocating for change. We are providing the clinical evidence that makes non-compliance structurally untenable.
WHO WE SERVE
Find the right information for your role
Medical Ethics operates a multi-platform information ecosystem aligned to stakeholder role and decision context.
INVESTORS & CORPORATE PARTNERS
Platform strategy, regulatory pipeline, licensing model, evidence base, and partnership opportunities. All information on this site is designed for investors, policymakers, and institutional partners.
Veterinarians & scientists
Full clinical evidence, peer-reviewed publications, species-specific protocols, formulation data, and prescribing information, will be available on our soon to be launched Tri-Solfen® website. It will be a dedicated resource for veterinary and scientific audiences. In the meantime contact us directly.
Policy makers & governments
Regulatory integration pathways, FMD treatment evidence, One Health and AMR alignment, and disease programme support across Africa and Asia. See our two market contexts.
Farmers & producers
Global platform focused on education, practical support, and adoption of pain mitigation practices in livestock production.
Our Partners
“We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use Tri-Solfen to ensure they get the best care.”
Clinton Wise
Wililoo Merino Stud, Woodanilling, W.A.
"Animal welfare is number 1 to us. We like to see our cattle happy. Tri-Solfen is helping us do that.
Dean Jones
Kanandah Station, Grafton NSW
"We think that animal pain should be eliminated, that is why we study novel products such as Tri-Solfen to use in the castration of livestock. "
Guido Bianco
Citterio Salami Factory, Italy